Curis Earnings Call Transcripts
Fiscal Year 2026
-
Four key proposals—including increasing authorized shares, approving stock conversions and warrants, and adopting a new incentive plan—were presented and all passed by majority vote. Final results will be filed in a Form 8-K.
Fiscal Year 2025
-
Q4 2025 saw a swing to net income due to a one-time gain from the Erivedge sale, with R&D and G&A expenses down year-over-year. PCNSL and CLL studies are prioritized, with initial CLL data expected at ASH 2026 and operations funded into H2 2027.
-
Steady progress in lymphoma, CLL, and AML studies with promising early data and regulatory engagement. Net loss narrowed year-over-year, expenses declined, and cash runway extends into 2026, though additional capital will be sought before year-end.
-
Emavusertib, a first-in-class IRAK4 inhibitor, shows strong proof-of-concept in PCNSL and AML, outperforming standard therapies and offering a favorable safety profile. Expansion into CLL, other NHL subtypes, and solid tumors is planned, with pivotal studies and new data expected soon.
-
The company is advancing a pivotal IRAK4/FLT3 inhibitor in PCNSL with strong early efficacy, aiming for accelerated approval and planning a confirmatory trial. Expansion into CLL and AML is underway, with a focus on combination therapies to improve response rates and enable time-limited treatment.
-
Emavusertib clinical programs advanced across PCNSL, CLL, AML, and MDS, with strong engagement from KOLs and promising early efficacy data. Net loss and expenses declined year-over-year, and recent financing extends the cash runway into Q1 2026.
-
Q1 2025 saw improved financials, strong clinical progress in PCNSL and AML, and the addition of Dr. Hamdy as CMO. Emavusertib showed promising efficacy, and cash runway extends into Q4 2025.
-
The IRAK4 program is advancing in PCNSL with a pivotal trial enrolling 30-40 more patients over 12-18 months, supported by strong mechanistic rationale and early efficacy signals. Expansion to other NHL indications and AML is planned, with key data updates expected at major conferences.
Fiscal Year 2024
-
Significant clinical and regulatory progress was made in NHL and AML, with emavusertib showing strong efficacy and receiving orphan drug designation. Financials improved year-over-year, and recent equity offerings extended the cash runway into Q4 2025.
-
Emavusertib showed promising early efficacy in PCNSL and FLT3-mutated AML, with ongoing FDA discussions for accelerated approval. Q3 net loss narrowed year-over-year, and recent financing extends cash runway into mid-2025.
-
IRAK4-targeted therapies are advancing in AML and NHL, with proof-of-concept data sets expanding and regulatory discussions ongoing. Early results in FLT3-mutated AML and primary CNS lymphoma are promising, and pivotal trial alignment with FDA is expected by year-end.
-
Emavusertib, a novel IRAK4 inhibitor, is showing promising safety and efficacy in NHL and AML, with a 50% response rate in relapsed/refractory PCNSL and durable activity in FLT3-mutated AML. Expansion into solid tumors and key clinical milestones are supported by a strong cash position.
-
Emavusertib showed promising early efficacy in both PCNSL and AML, with regulatory discussions advancing and orphan drug status granted in the EU. Net loss narrowed slightly year-over-year, and cash is expected to fund operations into Q1 2025.